Abstracts

406 – Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles

Background Human immunodeficiency virus (HIV) infection remains incurable due to latently infected cells resistant to anti-retroviral therapy (ART). One HIV cure strategy is to permanently silence the latent reservoir. The HIV Tat, trans-activator of transcription, protein promotes productive transcriptional elongation, enabling the rapid production of viral proteins and virions. Therefore, we sought to mutate the…

981 – Long-Term Use, HIV Testing & Effectiveness in Individuals on CAB LA PrEP in the Trio Health Cohort

Background Cabotegravir long-acting (CAB LA) is the first injectable approved for HIV pre-exposure prophylaxis (PrEP). This analysis assessed CAB LA PrEP use, HIV testing patterns, adherence and HIV acquisition in real world clinical setting. Methods Adults without HIV who initiated CAB LA for PrEP between December 2021-February 2025 were identified from the Trio Health Cohort.…

469 – Machine Learning-Derived Cognitive Subtypes of HIV: Results From the NIMH MIAAD-NHIV Initiative

Background The heterogeneity observed in cognitive symptoms among people with HIV (PWH) creates a challenge for translating research findings into effective clinical interventions. This study utilized a data-driven approach to identify cognitive subtypes and their clinical characteristics in an international sample of PWH who underwent cognitive assessment during acute or chronic infection. Methods Participants included…

1063 – PrEP Engagement and Persistence Among Heterosexual Men in Malawi: Findings From HPTN 112

Background Heterosexual men seeking STI services are vulnerable to HIV, yet few studies test strategies to retain these men on pre-exposure prophylaxis (PrEP). Peer-delivered systems navigation (SN) addresses barriers to health care access and may improve PrEP use but has not been tested among men in sub-Saharan Africa. Methods We present a type I effectiveness-implementation…

771 – Programmatic Effectiveness of TB Preventive Treatment for People With HIV: A Target Trial Emulation

Background In randomized clinical trials, tuberculosis preventive treatment (TPT) reduced TB incidence and mortality among people living with HIV (PLHIV); however, real-world impact has not been evaluated since the “treat all” era when antiretroviral therapy (ART) expanded to all PLHIV, regardless of CD4 count. We examined programmatic effectiveness of TPT among PLHIV in six high-TB-burden,…

538 – Five-Year Effectiveness of Doravirine-Based ART in Treatment-Experienced People Living With HIV

Background Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in treatment-experienced and naïve people living with HIV (PLWH). This study evaluated the long-term effectiveness of DOR-based antiretroviral therapy (ART) among treatment-experienced PLWH who were virologically suppressed (VS) prior to switch. Methods This retrospective cohort study included all VS (viral load (VL) <50 copies/mL) PLWH ≥18…

1010 – Baseline CD4 Count Influences HPV Vaccine Response in PWH: Two-Year Follow-Up

Background Data on HPV-specific T-cell responses to the nonavalent Gardasil 9® vaccine in people with HIV(PWH) are limited. Given the critical role of cellular mediated-immunity(CMI) in vaccine efficacy, we evaluated post-vaccination T-cell responses in virally suppressed PWH on ART, stratified by CD4 T-cell count at time of first vaccine dose. Methods We prospectively enrolled PWH…

1079 – Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya

Background Identifying HIV prevention needs is challenging. Common approaches (e.g., public health campaigns, HIV risk scores) have limited sensitivity. Sentiment analysis uses natural language processing, text analysis, and computational linguistics to identify and study affective states and subjective information. This study explored a novel use of sentiment analysis with WhatsApp messages to identify unrecognized HIV…

655 – Pitavastatin Effects on Lipids in Relation to MACE: A REPRIEVE Secondary Analysis

Background The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) demonstrated a 36% reduction in major adverse cardiovascular events (MACE) with pitavastatin among people with HIV (PWH). Little is known about the relationship between lipid-lowering and MACE in this population. We evaluated pitavastatin effects on lipids and examined mediation of pitavastatin effects on MACE…